EDUCATION

07/2001-05/2007  – Wake Forest University School of Medicine, United States of America

                            – Ph.D., Cancer Biology

                            – Thesis advisor: Frank M. Torti, M.D.

                            – Research project: Iron metabolism and cancer

09/1998-06/2001  – Shandong University School of Medicine, P.R. China

                            – Master, Human Anatomy and Histology & Embryology

                            – Thesis advisor: Zhiyu Liu, M.D.

                            – Research project: VEGF-C and breast cancer metastasis

09/1993-07/1998  – Shandong University School of Medicine, P.R. China

                            – M.D.

POSTGRADUATE EXPERIENCE

07/2016 –              – Assistant Professor, Tenure track

                                Department of Hematopathology

                                The University of Texas MD Anderson Cancer Center

                                Houston, Texas, 77030

07/2014 – 06/2016 – Hematopathology fellow

                                Department of Hematopathology

                                The University of Texas MD Anderson Cancer Center

                                Houston, Texas, 77030

07/2010 – 06/2014 – Pathology resident (AP/CP)

                                Department of Pathology

                                Wake Forest University Baptist Medical Center

                                 Winston Salem, NC, 27157

06/2007-06/2010 – Postdoctoral Research Fellow

                              Department of Cancer Biology

                              Wake Forest University School of Medicine

                              Winston Salem, NC, 27157

MEDICAL LICENSURE AND CERTIFICATION

2016                        – Texas Medical license

2014                        – Pennsylvania Medical license

2009                        – ECFMG certification

MEDICAL BOARD CERTIFICATION

2014                        – American Board of Pathology, AP/ CP

2015                        – American Board of Pathology, Hematopathology MEMBERSHIPS IN PROFESSIONAL SOCIETIES

    1. International BioIron Society

    2. College of American Pathologists

    3. American Society for Clinical Pathology

    4. The Society for Hematopathology and the European Association for Haematopathology

    5. United States and Canadian Academy of Pathology

INVITED JOURNAL REVIEWER

    BMC Cancer

    Journal of Hematology & Oncology

    Scientific Reports

    OncoTargets and Therapy

    Journal of Cellular and Molecular Medicine

    Case Reports in Hematology

HONORS AND AWARDS

2016         – The Kimberly Patterson Endowed Fellowship in Leukemia Research Award

2016         – Best Abstract Award – 1st Place, The Chinese American Pathologists Association

                   Annual Meeting, Seattle, WA

2016         – Platform Presentation – 1st Place, Texas Society of Pathologists 95th Annual           

                   Meeting, Dallas, TX

2015         – Best Poster Award– 3rd Place, Society of Hematologic Oncology Annual Meeting,

                   Houston, TX

2007         – Annual Retreat Presentation – 1st Place, Department of Cancer Biology at Wake

                   Forest University School of Medicine

2001-2002 – Graduate Fellowship, Wake Forest University School of Medicine

1993-1998 – Medical Student Scholarship, Shandong University School of Medicine

CLINICAL EXPERIENCE AT OUTSIDE INSTITUTES

    10/2012 Hematopathology Section, National Cancer Institute, NIH

PATENTS AND TECHNOLOGY LICENSES

    1. Flow Cytometry-Based Detection of Fusion Oncogenes Associated with Hematopoietic Disorders. Ken Tian, Wei Wang, Michael Beaty, David Grier, Natalie Walker, James Wood. (filed in 06/2014)

    2. Non-exclusive license agreement with EMD Millipore for an antibody to Ferritin H, a marker of erythroid precursors and macrophages. Wei Wang, Suzy Torti, Frank Torti, and Michael Beaty. (07/2013) (Millipore Cat No # : MABC602)

DEPARTMENTAL ACTIVITIES DURING RESIDENCY TRAINING

    1. Founder and Organizer, Hematopathology Unknown Conference (2012-2013)

    2. Organizer, California Tumor Tissue Registry (CTTR) Unknown Conference (2012-2014)

    3. Organizer, Hematopathology Spring Course (Jan – Apr, 2013)

FUNDED PROJECTS DURING RESIDENCY AND FELLOWSHIP TRAINING

2010 – 2011 Mitochondrial dysfunction in histiocytoid cardiomyopathy

                  $3,500

                  Investigator: Wang, W., Manavi, C., Lantz, P., and Laudadio, J.

2012 – 2014 Iron-related proteins as markers for erythroid precursors and lymphoma-

                  Associated macrophages

                  $10,500

                  Investigator: Wang, W., and Beaty, MW.

2013 – 2014 The diagnostic role of gamma-delta T cells in early stage celiac disease

                   $4500

                   Investigator: Wang, W., and DeRoche, T.

2015-           The diagnostic and mechanistic role of ferritin in acute leukemia

                   $10,000

                   Investigator: Wang, W., Zuo, Z., and Bueso-Ramos, C.

TEACHING ACTIVITIES

12/2013     Topic: Slide teaching of hematopoietic disease

                 To: 2nd year Medical students at Wake Forest University School of Medicine

04/2013     Topic: Malignant hematopoietic disorders

                 To: PhD students at Wake Forest University School of Medicine

10/2012     Topic: Cardiovascular Pathology

                 To: Physical Therapy students at Wake Forest University School of Medicine

01/2000     Topic: Human Anatomy and Histology

                 To: 1st year Medical students at Shandong University School of Medicine

PUBLICATIONS

JOURNAL ARTICLES:

1. Tang, Z., Coexistent Genetic Alterations Involving ALK, RET, ROS1 or MET in 15 Cases of Lung Adenocarcinoma. Modern Pathology

2. Gong, Z., Medeiros, LJ., Cortes, JE., Zheng, L., Khoury, JD., Wang, W., Tang, G., Loghavi, S., Luthra, R., Yang, W., Kantarjian, HM., and Hu, S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer Journal (2017) 7, e583; doi:10.1038/bcj.2017.62

3. Quesada, A., Desai, PA., Lin, P., Westin, JR., Hawsawi, HM., Wei, P., Tang, G., Seegmiller, A., Reddy, N., Yin, C., Zuo, Z., Wang, W., Xu, J., Miranda, R., Medeiros, LJ. Increased MYC Copy Number Predicts a Worse Outcome in Patients with Diffuse Large B-Cell Lymphoma. Modern Pathology. 2017, accepted

4. Wang, W., Routbort, MJ., OK CY., Patel, KP., Sun, Y., Kanagal-Shamanna R., Medeiros, LJ., and Wang, SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24786. [Epub ahead of print]

5. Montenegro-Garreaud, X., Miranda, RN., Reynolds A., Tang, G., Wang, SA., Yabe, M., Wang, W., Fang, L., Bueso-Ramos, CE, Lin, P., Medeiros LJ., Lu, X. Myeloproliferative Neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: A Meta-Analysis of 20 Cases Shows Cytogenetic Progression with B-Lymphoid Blast Phase. Hum Pathol. 2017 May 24. [Epub ahead of print]

6. Hu, Z., Medeiros, LJ., Wang, W., Chen, Z., Tang, G., Hodjat, P., Yang, S., Fang, L., Li, Y., Verstovsek S., and Hu, S. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. Modern Pathology, advance online publication 24 March 2017

7. Salem, A., Loghavi, S., Tang, G., Huh, YO., Jabbour, EJ., Kantarjian, H., Wang, W., Hu, S., Luthra, R., Medeiros, LJ., and Khoury, JD. Myeloid Neoplasms with Concurrent BCR-ABL1 and CBFB Rearrangements: A Series of 10 Cases of a Clinically Aggressive Neoplasm. Am J Hematol. 2017 Mar 2. doi: 10.1002/ajh.24710. [Epub ahead of print]

8. Pina Oviedo, S., Wang, W., Manning, J., and Medeiros, LJ. Follicular Lymphoma with Hyaline-vascular Castleman Disease-like Follicles and CD20-Positive Follicular Dendritic Cells. Pathology, 2017, [Epub ahead of print]

9. Wang, W., Wang, SA., Medeiros, LJ., and Khoury JD. Pure erythroid leukemia. Am J Hematol. 2017 Mar;92(3):292-296.

10. Chen, Z., Medeiros, LJ., Kantajian, HM., Zheng, L., Gong, Z., Patel, KP., Xiong, H., Wang, W., Cortes JE., and Hu, S. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer Journal (2017) 7, e521

11. Gong, Z., Zheng, L., Tang, Z., Chen, Z., Wang, W., Bai, S., Tang, G., Medeiros, LJ., and Hu, S. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol (2017) 96:501–504

12. Hu, Z., Medeiros, LJ., Chen, Z., Chen, W., Li, S., Konoplev, SN., Lu, X., Pham, LV., Young, KH., Wang, W., and Hu, S. et al . Mantle Cell Lymphoma with MYC Rearrangement: A Report of 17 Patients. Am J Surg Pathol. 2017 Feb;41(2):216-224.

13. Gong, Z., Xie, W., Wang, W., Chen, Z., Xu, J., Yuan, J., Zhou, Y., Wang, D., Medeiros, LJ., and Hu, S. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases. International Journal of Laboratory Hematology. 2016 Nov 13. doi: 10.1111/ijlh.12605.

14. Hu, Z., Sun, Y., Wang, W., Medeiros, LJ., and Kanagal, R. Refractory Hairy Cell Leukemia-Variant. American Journal of Hematology. 2016 DOI: 10.1002/ajh.24580

15. Messer, A.,, Jenkinson, H., Wang,W., and Duvic, M. New B-Cell Lymphomas in the Setting of a Previous Rare Breast Implant-Associated B-Cell Lymphoma. Plastic and Reconstructive Surgery. 2016 Nov; 4(11): e1148.

16. Wang, W., Chen, Z., Hu, Z., Yin, CC., Li, S., Bai, S., Bueso-Ramos, CE., Medeiros, LJ., and Hu, S. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J. 2016 Nov; 6(11): e490.

17. Chen, Z., Shao, C., Wang, W., Zuo Z., Mou X., Hu SJ., DiGiuseppe, JA., Zu, Y., Medeiros, LJ., and Hu, S. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.2016 Sep 2. doi: 10.1038/leu.2016.231.

18. Fang, L., Hu Y, Wang W, Hu S, Zhang LI, Wang R. Development of multiple malignancies following long-term glucocorticoid therapy in a patient with leukocytoclastic vasculitis: A case report. Mol Clin Oncol.2016;4(6):929-932.

19. Miao, Y., Lin, P., Wang, W., Medeiros, LJ., and Lu, X. CCND1-IGH fusion-amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma: A Case Report. American Journal of Clinical Pathology. 2016; 146:747-752.

20. Miao, Y., Hu, S., Lu X., Li, S., Wang, W., Medeiros, LJ., and Lin, P. Double-hit Follicular Lymphoma with MYC and BCL2 Translocations: A Study of 7 Cases with a Review of Literature. Human Pathology. 2016 Dec;58:72-77.

21. Tang, Z., Medeiros, LJ., Yin, CC., Wang, W., Lu, X., Young, KH., Khoury, J., and Tang, G. Sex Chromosome Loss after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Hematologic Neoplasms: A Diagnostic Dilemma for Clinical Cytogeneticists. Molecular Cytogenetics. 2016; 9: 62.

22. Quesada, AE., Huh, Y., Wang, W., Medeiros, LJ., and Thakral, B. Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma in a patient treated with azathioprine for ulcerative colitis. Pathology. 2016 Aug;48(5):513-5.

23. Masarova, L., Wang,W., Newberry, KJ., Kantarjian, H., and Verstovsek, S. Complete remission in a patient with JAK2 and IDH2 positive myelofibrosis. Blood. 2016 Aug 11;128(6):877-80..

24. Chen, Z., Wang, W., Liu, E., Zhao, C., Yuan, J., Lu, X., Dadfarnia, M., Medeiros, LJ., and Hu, S. Differential impact of extramedullary myeloid sarcoma versus medullary blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Blood Cancer Journal. 2016 May 6;6:e418.

25. Wang, W., Cortes, JE., Tang, G., Khoury, J., Wang, S., Bueso-Ramos, C., DiGiuseppe, JA., Chen, A., Kantarjian, HM., Medeiros, LJ., and Hu, S. Risk stratification of additional cytogenetic changes in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Jun 2;127(22):2742-50.

26. Wang, W., Tang, G., Kadia, T., Lu, X., Li, Y., Huang, L., Montenegro, X., Miranda, R., Wang, S. Cytogenetic evolution associated with disease progression in hematopoietic neoplasms with t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement. Journal of National Comprehensive Cancer Network. 2016 Jun 1; 14(6):708-11.

27. Khandakar, B., Wang, W., and Li, S. Primary Splenic Red Pulp Diffuse Large B-cell Lymphoma with Anaplastic Features. Stem Cell Investigation. 2016; 3: 9.

28. Wang, W., Ali, S., Tang, Z., Miranda, RN., Medeiros, LJ., and Hu, S. Constitutional pericentric inversion of chromosome 9 is associated with a good treatment response and has no negative impact on survival in chronic myelogenous leukemia. Annals of Hematology. 2016 Mar;95(4):657-9.

29. Chen, Z., Cortes, JE., Jorgensen, JL., Wang, W., Yin, CC., You, MJ., Jabbour, E., Kantarjian, HM., Medeiros, LJ., and Hu, S. Differential impact of additional chromosomal abnormalities in myeloid versus lymphoid blast phase of chronic myelogenous leukemia. Leukemia. 2016 Jul;30(7):1606-9.

30. Jain, P., Verstovsek, S., Wang, W., Loghavi, S., Torres, A., Estrov, Z., Patel, P., Pemmaraju, N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia & Lymphoma.2016 Aug;57(8):1969-73.

31. Chen, Z., Wang, W., Verstovsek, S., Cortes, JE., Medeiros, LJ., and Hu, S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation positive myeloproliferative neoplasms. International Journal of Laboratory Hematology. 2015 Dec;37(6):e150-2.

32. Wang, W., Cortes, JE., Lin, P., Khoury, J., Ai D., Tang, Z., Tang, G., Jorgensen, JL., Medeiros, LJ., and Hu, S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Leukemia. 2015 Nov;29(11):2263-6.

33. Zhou, X., Zhang, J., Yun, H., Shi, R., Wang, Y., Wang, W., Lagercrantz S., and Mu, H. Alternations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015 Nov 3;6(34):36894-36902.

34. Liu, H., Wang, W., Tang, G.,Yin, CC., Muzzafar, T., Medeiros, LJ., Hu,S. Lymphomatous Variant of Hairy Cell Leukemia: a Distinctive Presentation Mimicking Low-Grade B-Cell Lymphoma. Histopathology. 2015 Nov;67(5):740-5.

35. Wang, W., Cortes, JE., Lin, P., Beaty, MW., Ai, D., Amin, HM., McDonnell, TJ., Kantarjian, HM., Medeiros, LJ., and Hu, S. Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Blood. 2015 Oct 1;126(14):1699-706.

36. Wang, W., Xie, W., and Hu, S. Cup-like blasts in B-lymphoblastic leukemia. British Journal of Hematology. 2015 Sep;170(5):596.

37. Chen, Z., Wang, W., Rich, A., Tang, G., and Hu, S. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: a report of 11 cases. American Journal of Hematology. 2015 Aug; 90(8):E146-8.

38. Wang, W., Hu, S., Lu, X., Young, KH., and Medeiros, LJ. Triple-Hit B-Cell lymphomas with MYC, BCL2 and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. The American Journal of Surgical Pathology. 2015 Aug; 39(8):1132-9.

39. Jaitly, V., Wang, W., and Hu, S. Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia. Stem Cell Investigation. 2015 July; 2:13.

40. Wang, W., and Hu, S. Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32) (BloodWork). Blood. 2015 Apr 30; 125 (18).

41. Wang, W., Tang, G., Cortes, JE., Liu, H., Ai, A., Li, S., Khoury, J., Bueso-Ramos, C., Medeiros, LJ., and Hu, S. Chromosomal Rearrangement Involving 11q23 Locus in Chronic Myelogenous Leukemia: a rare phenomenon frequently associated with poor prognosis. Journal of hematology & oncology. 2015 Apr 8; 8(1):32.

42. Wang, W., Deng, Z., Hatcher, H., Miller, L., Di, X., Tesfay, L., Sui, G., Torti, SV., and Torti, FM. IRP2 regulates breast cancer growth. Cancer Research. 2014 Jan; 74(2): 497-507.

43. Wang, W., Woo, J., Grier, D., Sui, G., Pardee, TS., Torti, SV., Torti, FM., and Beaty, MW. Ferritin H is a novel marker of macrophages and erythroid precursors. Histopathology. 2013 May;62(6):931-40.

44. Wang, W., Pardee, TS., and Beaty, MW. Subcutaneous panniculitis-like T-cell lymphoma with mesenteric involvement. Journal of Hematopathology. 2012 Sep; 6(3):155-159.

45. Wan, M., Huang, W., Kute, TE., Miller, LD., Zhang, Q., Hatcher, H., Wang, J., Stovall, DB., Russell, GB., Cao, P., Deng, Z., Wang, W., Zhang, Q., Lei, M., Torti, SV., Akman, SA., Sui, G. Yin Yang 1 Plays an Essential Role in Breast Cancer and Negatively Regulates p27. Am J Pathol. 2012 May;180(5):2120-33.

46. Wang, W., Manavi, C., Pang, C., Koty, P., Pettenati, MJ. +7 or trisomy 7 (solely). Atlas Genet Cytogenet Oncol Haematol. March 2012.

47. Persad, P., Manavi, C., Beaty, M., Wang, W., Pettenati, MJ. idic(7)(q11.2). Atlas Genet Cytogenet Oncol Haematol. March 2012 .

48. Han, J., Seaman, WE., Di, X., Wang, W., Willingham, M., Torti, FM., Torti, SV. Iron Uptake Mediated by Binding of H-Ferritin to the TIM-2 Receptor in Mouse Cells. PLoS ONE. 2011 6(8): e23800.

49. Pinnix, ZK., Miller, LD,, Wang, W., D'Agostino, R Jr., Kute, T., Willingham, MC., Hatcher, H., Tesfay, L., Sui, G., Di, X., Torti, SV., Torti, FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Science Translational Medicine. 2010 Aug 4;2(43):43-56.

50. Wang, W., Di, X., Torti, SV., Torti, FM. Ferritin H induction by histone deacetylase inhibitors. Biochem Pharmacol. 2010 Aug 1;80(3):316-24.

51. Wang, W., Knovich, MA., Coffman, LG., Torti, FM., Torti, SV. Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010 Aug;1800(8):760-9.

52. Jiao, Y., Wilkinson, J 4th., Di, X., Wang, W., Hatcher, H., Kock, ND., D'Agostino, R Jr., Knovich, MA., Torti, FM., Torti SV. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009 Jan 8; 113 (2): 462-9.

9

53. Zhang, F., Wang, W. (Co-1st author), Tsuji, Y., Torti, SV., Torti, FM. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. Journal of Biological Chemistry. 2008 Dec 5; 283(49):33911-8.

54. Dos Santos, CO., Dore, LC., Valentine, E., Shelat, SG., Hardison, RC., Ghosh, M., Wang, W., Eisenstein, RS., Costa, FF., Weiss, MJ. An iron responsive element-like stem-loop regulates alpha-hemoglobin-stablizing protein mRNA. Journal of Biological Chemistry. 2008 Oct 3; 283(40): 26956-64.

55. Blish, KR., Wang, W., Willingham, MC., Du, W., Birse, CE., Krishnan, SR., Brown, JC., Hawkins, GA., Garvin, AJ., D'Agostino, RB Jr., Torti, FM., Torti, SV. A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Molecular Biology of the Cell. 2008 Feb; 19(2): 457-64.

56. Wang, W., Di, X., D'Agostino, RB Jr., Torti, SV., Torti, FM. Excess capacity of the iron regulatory protein system. Journal of Biological Chemistry. 2007 Aug 24; 282 (34): 24650-9.

57. Jiao, Y., Wilkinson, J 4th., Christine, PE., Buss, JL., Wang, W., Planalp, R., Torti, FM., Torti, SV. Iron chelation in the biological activity of curcumin. Free Radical Biology and Medicine. 2006 April 1; 40(7): 1152-1160.

58. Wang, W., Liu, Z., Ding, H., Gao, J., Bi, Y., Wang, D., Di, X. VEGF-C expression in breast cancer and its relationship to lymph node metastasis. Chinese Journal of Anatomy. 2001;24(5): 425-428.

59. Di, X., Li, Z., Yang, L., Sun, J., Wang, W. Effects of the rat’s serum with Bu Yang Huan Wu Tang on peripheral nerve regeneration. Journal of Clinical Rehabilitative Tissue Engineering Research. 2001; 5(24): 58-61.

SELECTED ABSTRACTS:

1. Wang, W., Cortes, JE., Lin, P., Khoury, J., Ai D., Tang, Z., Tang, G., Jorgensen, J., Medeiros, LJ., and Hu, S. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Society of Hematologic Oncology annual meeting, 2015, Houston, United States.

2. Wang, W., Cortes, JE., Lin, P., Beaty, MW., Ai, D., Amin, HM., McDonnell, TJ., Kantarjian, HM., Medeiros, LJ., and Hu, S. Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors. Society of Hematologic Oncology annual meeting, 2015, Houston, United States.

3. Wang, W., Hu, S., Lu, X., Young, KH., and Medeiros, LJ. Triple-Hit B-Cell Lymphomas with MYC, BCL2 and BCL6 Translocations: Morphological, Immunophenotypical, and Clinical Features. 104th United States & Canadian Academy of Pathology (USCAP) annual meeting, 2015, Boston, United States.

10

4. Wang, W., Ai, A., Tang, G., Liu, H., Bueso-Ramos, C., Medeiros, LJ., and Hu, S. Balanced 11q23/MLL Rearrangement in Chronic Myelogenous Leukemia. 104nd United States & Canadian Academy of Pathology (USCAP) annual meeting, 2015, Boston, United States.

5. Rich, A., Ai, D., Wang, W., You, J., Yin, CC., Bueso-Ramos, C., Medeiros, LJ., and Hu, S. Pediatric chronic myelogenous leukemia in tyrosine kinase inhibitor era. 104nd United States & Canadian Academy of Pathology (USCAP) annual meeting, 2015, Boston, United States.

6. Wang, W., Bergman, S., Hurd, D., Zamkoff, K., and Beaty, MW. Large granular lymphocytic leukemia after allogeneic hematopoietic stem cell transplant. 103nd United States & Canadian Academy of Pathology (USCAP) annual meeting, 2014, San Diego, United States.

7. Wang, W., Pettenati, M., and Pang, C. B lymphoblastic leukemia with t(5;14)(q31;q32). The Society for Hematopathology and European Association for Haematopathology Workshop, 2013, Houston, United States.

8. Wang, W., Holley, C., Pettenati, M., Grier, D., and Beaty, MW. Acute promyelocytic leukemia with PML-RARA rearrangement, FISH negative. The Society for Hematopathology and European Association for Haematopathology Workshop, 2013, Houston, United States.

9. Wang, W., Manavi, C., and Grier, D. Acute leukemia with t(9;11)(p22;q23): presented with myeloid sarcoma and relapsed as acute lymphoblastic leukemia. The Society for Hematopathology and European Association for Haematopathology Workshop, 2013, Houston, United States.

10. Wang, W., Holley, C., Pettenati, M., Grier, D., and Beaty, MW. Acute myeloid leukemia with t(9;22)(q34;q11.2), favor therapy-related. The Society for Hematopathology and European Association for Haematopathology Workshop, 2013, Houston, United States.

11. Wang, W., Torti, FM., Torti, SV., and Beaty, MW. Ferritin H is a novel marker of tumor-associated macrophages and its expression is associated with tumor grade. 102nd United States & Canadian Academy of Pathology (USCAP) annual meeting, 2013, Baltimore, United States.

12. Wang, W., Torti, SV., Torti, FM., and Beaty, MW. Ferritin H is a maker of erythroid precursors in bone marrow biopsy specimens. XVI Meeting of the European Association for Haematopathology, 2012, Lisbon, Portugal.

13. Wang, W., Pardee, TS., and Beaty, MW. Subcutaneous panniculitis-like T-cell lymphoma with mesenteric involvement. XVI Meeting of the European Association for Haematopathology, 2012, Lisbon, Portugal.

11

14. Wang, W., Grier, D., Woo, J., and Beaty, MW. Ferritin H is a novel marker of macrophages. American Society for Clinical Pathology (ASCP), 2012, Boston, United States.

15. Wang, W., Pang, CS. Peripheral T-cell lymphoma with aberrant expression of CD20 and CD79a. XVI Meeting of the European Association for Haematopathology, 2012, Lisbon, Portugal.

16. Wang, W., Deng, Z., Torti, SV., Torti, FM. The mechanisms of IRP2 overexpression in breast cancer. College of American Pathologists Annual Meeting (CAP), 2012, San Diego, United States.

17. Wang, W., Hatcher, H., Deng, Z., Di, X., Tesfay, L., Torti, SV., Torti, FM. The Role of Iron Regulatory Protein 2 in Breast Cancer. College of American Pathologists Annual Meeting (CAP), 2011, Dallas, United States.

18. Wang, W., Di, X., Torti, SV., and Torti, FM. Ferritin H induction by histone deacetylase inhibitors. International Bioiron Society meeting, 2009, Porto, Portugal.

19. Torti, FM., Wang, W., Di, X., and Torti, SV. Extensive excess capacity of the IRP system in cellular iron regulation. International Bioiron Society meeting, 2007, Kyoto, Japan.

20. Pang, B., Wang, W., Torti, SV., Torti, FM., and Berquin, IM. Ferritin H regulation by YB-1 in human mammary epithelial cells. Proc Amer Assoc Cancer Res, 2004, Orlando, Florida.